Related Experiment Video
Updated: Aug 13, 2026

Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
[Analgesia by sublingual buprenorphine in extracorporeal kidney lithotripsy]
P Tauzin-Fin1, S Saumtally, M C Houdek
1Departement d'Anesthésie-Réanimation III, Hôpital Pellegrin-Tripode, Bordeaux.
Abstract:
The efficacy of sublingual buprenorphine given for premedication was assessed in 287 consecutive patients scheduled for extracorporeal shock wave lithotripsy (ESWL). The patients were randomly assigned to three groups. They were given 45 min before starting ESWL 5 mg midazolam orally in group 1 (n = 97), and 5 mg midazolam orally and 0.2 mg sublingual buprenorphine in group 2 (n = 97), and 5 mg midazolam orally and 0.4 mg sublingual buprenorphine in group 3 (n = 93). Analgesia was assessed with a simple three step verbal scale: no pain, moderate pain treated with simple analgesics (Spasfon, Viscéralgine), and exquisite pain requiring general anaesthesia. Sublingual buprenorphine provided good analgesia in 87% of group 2 patients, and 88% of group 3 patients (NS) whereas 70% of group 1 patients experienced no pain (p < 0.05). The incidence of side-effects during the 12 h following ESWL, such as nausea, vomiting and drowsiness, was higher in group 3 (31 patients) than in group 2 (13 patients) (p > 0.01). No clinical respiratory depression occurred, although 11 patients in group 3 complained of drowsiness. It is concluded that premedication with 0.2 mg of sublingual buprenorphine provides efficient analgesia for ESWL and few side-effects.
More Related Videos
Related Concept Videos
Drug Elimination by Renal Route: Tubular Reabsorption
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Urinary Tract Calculi VI: Surgical Management
Kidney Transplant II: Surgical Procedure

